{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T14:01:39Z","timestamp":1790085699437,"version":"4.0.1"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    <jats:italic>In situ<\/jats:italic>\n                    vaccination (ISV) is a local tumor-directed immunotherapy strategy that uses a treated tumor as an endogenous, patient-specific source of tumor antigens and a site of immune activation, with the goal of converting local treatment into systemic and durable antitumor immunity. Depending on the modality, ISV induces immunogenic cell death, other forms of tumor-cell stress or death, or local innate immune activation, thereby increasing antigen availability, promoting type I interferon signaling, and supporting dendritic cell\u2013mediated cross-priming of tumor-reactive T cells capable of mediating both local and systemic antitumor immunity, including regression of untreated lesions. Across immunocompetent preclinical models, ISV can generate durable local tumor control, abscopal responses, and long-term immune memory, particularly when combined with modalities that amplify antigen release or inflammatory signaling. Early clinical studies employing intratumoral innate immune agonists, radiotherapy-based regimens, cytokines, and oncolytic viruses demonstrate clinical feasibility, favorable safety profiles, and emerging evidence of systemic efficacy in selected tumor types. In this review, we discuss the immunologic principles underlying ISV and organize the field according to major triggering modalities, including radiotherapy, ablation, and light-based therapies, selected chemotherapies, innate immune agonists, cytokines, and oncolytic viruses. We further highlight emerging intratumoral delivery platforms, such as lipid nanoparticles, injectable hydrogels, and biodegradable scaffolds, that enable precise spatial and temporal control of immune activation within the tumor microenvironment. Finally, we review the evidence that locally initiated antitumor immunity can extend beyond the treated lesion to control untreated lesions and metastatic disease, and discuss the challenges associated with achieving durable systemic efficacy and preventing recurrence.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1862956","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:15:44Z","timestamp":1790082944000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["In situ vaccination for the treatment of localized cancer and the prevention of metastatic disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Sangbeom","family":"Lee","sequence":"first","affiliation":[{"name":"Center for Cancer Prevention, Houston Methodist Cancer Center, Houston Methodist Research Institute","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moonhae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Kinesiology, Rice University","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yian","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Cancer Prevention, Houston Methodist Cancer Center, Houston Methodist Research Institute","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryon","family":"Johnson","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin","place":["Milwaukee, WI, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"You","sequence":"additional","affiliation":[{"name":"Center for Cancer Prevention, Houston Methodist Cancer Center, Houston Methodist Research Institute","place":["Houston, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0275-8","article-title":"Dissecting the mechanisms of immune checkpoint therapy","volume":"20","author":"Sharma","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B4","article-title":"The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170274","article-title":"T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy","volume":"113","author":"Houot","year":"2009","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nri.2016.107","article-title":"Immunogenic cell death in cancer and infectious disease","volume":"17","author":"Galluzzi","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164206","article-title":"Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T-cell immunity","volume":"322","author":"Hildner","year":"2008","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100348","article-title":"Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells","volume":"207","author":"Bachem","year":"2010","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2016.06.003","article-title":"Critical role for CD103+\/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T-cell immunity in melanoma","volume":"30","author":"Roberts","year":"2016","journal-title":"Cancer Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2018.6","article-title":"Using immunotherapy to boost the abscopal effect","volume":"18","author":"Ngwa","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1894","article-title":"Photodynamic therapy and anti-tumour immunity","volume":"6","author":"Castano","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19113480","article-title":"Anthracyclines as topoisomerase II poisons: from early studies to new perspectives","volume":"19","author":"Marinello","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf6290","article-title":"ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation","volume":"7","author":"Yang","year":"2021","journal-title":"Sci Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00524-z","article-title":"The cGAS-STING pathway as a therapeutic target in inflammatory diseases","volume":"21","author":"Decout","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.04.031","article-title":"Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity","volume":"11","author":"Corrales","year":"2015","journal-title":"Cell Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized interleukin-12 for cancer immunotherapy: a review of delivery strategies to potentiate efficacy and limit toxicity","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2015.10.016","article-title":"In situ vaccination: cancer immunotherapy both personalized and off-the-shelf","volume":"9","author":"Hammerich","year":"2015","journal-title":"Mol Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.6789","article-title":"Concurrent trastuzumab and HER2\/neu-specific vaccination in patients with metastatic breast cancer","volume":"27","author":"Disis","year":"2009","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-020-03331-6","article-title":"Effects of alpha-fetoprotein on the occurrence and progression of hepatocellular carcinoma","volume":"146","author":"Zheng","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040615","article-title":"Selecting target antigens for cancer vaccine development","volume":"8","author":"Buonaguro","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2025.102891","article-title":"Melanoma-associated antigen A4: a cancer\/testis antigen as a target for adoptive T-cell receptor T-cell therapy","volume":"134","author":"Knafler","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8697","article-title":"Targeting a neoantigen derived from a common TP53 mutation","volume":"371","author":"Hsiue","year":"2021","journal-title":"Science"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0954","article-title":"A multivalent BCR-ABL fusion peptide vaccination trial in patients with chronic myeloid leukemia","volume":"103","author":"Cathcart","year":"2004","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/sj.cdd.4402269","article-title":"Molecular characteristics of immunogenic cancer cell death","volume":"15","author":"Tesniere","year":"2008","journal-title":"Cell Death Differ"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1038226","article-title":"Immunogenic cell death: the cornerstone of oncolytic viro-immunotherapy","volume":"13","author":"Palanivelu","year":"2023","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2412876","article-title":"Trial watch: anticancer vaccination with dendritic cells","volume":"13","author":"Borges","year":"2024","journal-title":"Oncoimmunology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.ccell.2021.10.008","article-title":"Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulation","volume":"39","author":"Duraiswamy","year":"2021","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.10.3153","article-title":"Blockade of CD86 and CD40 induces alloantigen-specific immunoregulatory T cells that remain anergic even after reversal of hyporesponsiveness","volume":"95","author":"Koenen","year":"2000","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.03.017","article-title":"The abscopal effect associated with a systemic anti-melanoma immune response","volume":"85","author":"Stamell","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.10.019","article-title":"STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors","volume":"41","author":"Deng","year":"2014","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9793","article-title":"In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study","volume":"28","author":"Brody","year":"2010","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355222","article-title":"In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1\/2 study","volume":"119","author":"Kim","year":"2012","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.2229","article-title":"Safety and clinical activity of pembrolizumab and multisite stereotactic body radiotherapy in patients with advanced solid tumors","volume":"36","author":"Luke","year":"2018","journal-title":"J Clin Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1478","article-title":"Effect of pembrolizumab after stereotactic body radiotherapy vs pembrolizumab alone on tumor response in patients with advanced non-small cell lung cancer: results of the PEMBRO-RT phase 2 randomized clinical trial","volume":"5","author":"Theelen","year":"2019","journal-title":"JAMA Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1006\/cryo.1997.2017","article-title":"Minimally invasive cryosurgery\u2014technological advances","volume":"34","author":"Baust","year":"1997","journal-title":"Cryobiology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30050365","article-title":"Cryoablation and immunotherapy: an enthralling synergy for cancer treatment","volume":"30","author":"Medlej","year":"2023","journal-title":"Curr Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0190","article-title":"A pilot study of preoperative single-dose ipilimumab and\/or cryoablation in women with early-stage breast cancer with comprehensive immune profiling","volume":"22","author":"McArthur","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1562\/0031-8655(2001)074<0712:IOSNRI>2.0.CO;2","article-title":"Induction of systemic neutrophil response in mice by photodynamic therapy of solid tumors","volume":"74","author":"Cecic","year":"2001","journal-title":"Photochem Photobiol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603341","article-title":"Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity","volume":"95","author":"den Brok","year":"2006","journal-title":"Br J Cancer"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1782","article-title":"Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy","volume":"72","author":"Waitz","year":"2012","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1152934","article-title":"Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: an update review","volume":"14","author":"Zhai","year":"2023","journal-title":"Front Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2028","article-title":"Activation of the NLRP3 inflammasome in dendritic cells induces IL-1\u03b2-dependent adaptive immunity against tumors","volume":"15","author":"Ghiringhelli","year":"2009","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01692-4","article-title":"Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy","volume":"18","author":"Liu","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"Chiocca","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.coi.2018.03.008","article-title":"Oncolytic viruses and immunity","volume":"51","author":"Chaurasiya","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6265","article-title":"Measles virus induces oncolysis of mesothelioma cells and allows dendritic cells to cross-prime tumor-specific CD8 response","volume":"68","author":"Gauvrit","year":"2008","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"7149","DOI":"10.1038\/s41467-022-34791-8","article-title":"Expanding cross-presenting dendritic cells enhances oncolytic virotherapy and is critical for long-term anti-tumor immunity","volume":"13","author":"Svensson-Arvelund","year":"2022","journal-title":"Nat Commun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T-cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01510-7","article-title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial","volume":"27","author":"Dummer","year":"2021","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1963","article-title":"Phase I dose-escalation trial of MIW815 (ADU-S100), an intratumoral STING agonist, in patients with advanced\/metastatic solid tumors or lymphomas","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2021.01.001","article-title":"Granulocyte macrophage colony-stimulating factor has come of age: from a vaccine adjuvant to antiviral immunotherapy","volume":"59","author":"Petrina","year":"2021","journal-title":"Cytokine Growth Factor Rev"},{"key":"B60","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.1038\/s41467-019-11782-w","article-title":"A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control","volume":"10","author":"Sun","year":"2019","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0781","article-title":"Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects","volume":"19","author":"Fransen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan4488","article-title":"Eradication of spontaneous Malignancy by local immunotherapy","volume":"10","author":"Sagiv-Barfi","year":"2018","journal-title":"Sci Transl Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1382","article-title":"Neoadjuvant intratumoral immunotherapy with TLR9 activation and anti-OX40 antibody eradicates metastatic cancer","volume":"82","author":"Hong","year":"2022","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2768","article-title":"Neoadjuvant intratumoral plasmid IL-12 electro-gene-transfer and nivolumab in patients with operable, locoregionally advanced melanoma","volume":"30","author":"Tarhini","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32141","article-title":"First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid Malignancies","volume":"145","author":"Irenaeus","year":"2019","journal-title":"Int J Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2770","article-title":"A phase I clinical trial adding OX40 agonism to in situ therapeutic cancer vaccination in patients with low-grade B-cell lymphoma highlights challenges in translation from mouse to human studies","volume":"31","author":"Shree","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"7556","DOI":"10.1038\/ncomms8556","article-title":"Injectable cryogel-based whole-cell cancer vaccines","volume":"6","author":"Bencherif","year":"2015","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.71182","article-title":"Trivalent gadolinium ions forming injectable hydrogels for simultaneous in situ vaccination therapy and imaging of soft tissue sarcoma","volume":"15","author":"Wang","year":"2026","journal-title":"Adv Healthc Mater"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat9143","article-title":"Durable anticancer immunity from intratumoral administration of IL-23, IL-36gamma, and OX40L mRNAs","volume":"11","author":"Hewitt","year":"2019","journal-title":"Sci Transl Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"10635","DOI":"10.1038\/s41467-024-54877-9","article-title":"Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity","volume":"15","author":"Hamouda","year":"2024","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1448489","article-title":"Emerging prospects of mRNA cancer vaccines: mechanisms, formulations, and challenges in cancer immunotherapy","volume":"15","author":"Laila","year":"2024","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202101267","article-title":"Prevention of tumor growth and dissemination by in situ vaccination with mitochondria-targeted atovaquone","volume":"9","author":"Huang","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12500","article-title":"Mitochondria-targeted atovaquone promotes anti-lung cancer immunity by reshaping tumor microenvironment and enhancing energy metabolism of anti-tumor immune cells","volume":"44","author":"Xiong","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0410-x","article-title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","volume":"25","author":"Hammerich","year":"2019","journal-title":"Nat Med"},{"key":"B76","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/0008-5472.CAN-14-3619","article-title":"Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors","volume":"76","author":"Baird","year":"2016","journal-title":"Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness\u2014a literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"key":"B78","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s40425-019-0568-2","article-title":"Immunotherapeutic effects of intratumoral nanoplexed poly I:C","volume":"7","author":"Aznar","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B79","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","article-title":"Tumor-residing Batf3 dendritic cells are required for effector T-cell trafficking and adoptive T-cell therapy","volume":"31","author":"Spranger","year":"2017","journal-title":"Cancer Cell"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1038\/s41598-022-05702-0","article-title":"In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy","volume":"12","author":"Okada","year":"2022","journal-title":"Sci Rep"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd8636","article-title":"Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses","volume":"13","author":"Lo","year":"2021","journal-title":"Sci Transl Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0743","article-title":"In situ vaccination with a TLR9 agonist and local low-dose radiation induces systemic responses in untreated indolent lymphoma","volume":"8","author":"Frank","year":"2018","journal-title":"Cancer Discov"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.4015","article-title":"Toll-like receptor 4 agonist injection with concurrent radiotherapy in patients with metastatic soft tissue sarcoma: a phase 1 nonrandomized controlled trial","volume":"9","author":"Seo","year":"2023","journal-title":"JAMA Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-2502","article-title":"Safety, feasibility, and pharmacodynamic activity of intratumoral injections of the agonist anti-CD137 (4-1BB) mAb urelumab in combination with nivolumab","volume":"32","author":"Sanmamed","year":"2026","journal-title":"Clin Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40425-017-0276-8","article-title":"Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials","volume":"5","author":"Kaufman","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-3087","article-title":"Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy","volume":"16","author":"Alizadeh","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2444","article-title":"Carbon nanotubes enhance CpG uptake and potentiate anti-glioma immunity","volume":"17","author":"Zhao","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011173","article-title":"Topical TLR7 agonist and radiotherapy in patients with metastatic breast cancer","volume":"13","author":"Adams","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0469","article-title":"Intratumoral G100, a TLR4 agonist, induces antitumor immune responses and tumor regression in patients with Merkel cell carcinoma","volume":"25","author":"Bhatia","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx683","article-title":"Intratumoral immunotherapy: using the tumor as the remedy","volume":"28","author":"Marabelle","year":"2017","journal-title":"Ann Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy423","article-title":"Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT)","volume":"29","author":"Marabelle","year":"2018","journal-title":"Ann Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5286-0","article-title":"Patterns of clinical response with talimogene laherparepvec (T-VEC) in patients with melanoma treated in the OPTiM phase III clinical trial","volume":"23","author":"Andtbacka","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","volume":"34","author":"Puzanov","year":"2016","journal-title":"J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02595","article-title":"BO-112 plus pembrolizumab for patients with anti-PD-1-resistant advanced melanoma: phase II clinical trial SPOTLIGHT-203","volume":"43","author":"M\u00e1rquez-Rodas","year":"2025","journal-title":"J Clin Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2297453","article-title":"Toll-like receptor agonists as cancer vaccine adjuvants","volume":"20","author":"Jeon","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae200","article-title":"Phase I study of intratumoral injection of talimogene laherparepvec for the treatment of advanced pancreatic cancer","volume":"30","author":"Runcie","year":"2025","journal-title":"Oncologist"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0390","article-title":"Improving systemic delivery of oncolytic virus by cellular carriers","volume":"21","author":"Peng","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1038\/s41467-023-38651-x","article-title":"Synthetic virology approaches to improve the safety and efficacy of oncolytic virus therapies","volume":"14","author":"Azad","year":"2023","journal-title":"Nat Commun"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1862956\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:15:45Z","timestamp":1790082945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1862956\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":100,"alternative-id":["10.3389\/fimmu.2026.1862956"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1862956","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1862956"}}